A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Veliparib (Primary) ; Capecitabine; Temozolomide
- Indications Neuroendocrine tumours
- Focus Adverse reactions
- 26 Sep 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Jul 2017 Planned End Date changed from 1 Sep 2019 to 1 Feb 2020.
- 14 Jul 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Feb 2019.